Trial Profile
Integrating Personal and Household Environmental Hygiene Measures to Prevent Methicillin-Resistant Staphylococcus Aureus Infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Chlorhexidine (Primary) ; Mupirocin (Primary)
- Indications Bacterial skin diseases; Methicillin-resistant Staphylococcus aureus infections
- Focus Therapeutic Use
- Acronyms SHINE
- 27 Jul 2023 Planned End Date changed from 1 Sep 2023 to 1 Jun 2024.
- 27 Jul 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 22 Jul 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.